1
|
Knosalla C, Yazawa K, Behdad A, Bodyak N, Shang H, Bühler L, Houser S, Gollackner B, Griesemer A, Schmitt-Knosalla I, Schuurman HJ, Awwad M, Sachs DH, Cooper DKC, Yamada K, Usheva A, Robson SC. Renal and cardiac endothelial heterogeneity impact acute vascular rejection in pig-to-baboon xenotransplantation. Am J Transplant 2009; 9:1006-16. [PMID: 19422330 PMCID: PMC2824173 DOI: 10.1111/j.1600-6143.2009.02602.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Xenograft outcomes are dictated by xenoantigen expression, for example, Gal alpha1, 3Gal (Gal), but might also depend on differing vascular responses. We investigated whether differential vascular gene expression in kidney and cardiac xenografts correlate with development of thrombotic microangiopathy (TM) and consumptive coagulation (CC). Immunosuppressed baboons underwent miniswine or hDAF pig kidney (n = 6) or heart (n = 7), or Gal-transferase gene-knockout (GalT-KO) (thymo)kidney transplantation (n = 14). Porcine cDNA miniarrays determined donor proinflammatory, apoptosis-related and vascular coagulant/fibrinolytic gene expression at defined time points; validated by mRNA, protein levels and immunopathology. hDAF-transgenic and GalT-KO xenografts, (particularly thymokidneys) exhibited prolonged survival. CC was seen with Gal-expressing porcine kidneys (3 of 6), only 1 of 7 baboons postcardiac xenotransplantation and was infrequent following GalT-KO grafts (1 of 14). Protective-type genes (heme oxygenase-I, superoxide dismutases and CD39) together with von Willebrand factor and P-selectin were upregulated in all renal grafts. Transcriptional responses in Gal-expressing xenografts were comparable to those seen in the infrequent GalT-KO rejection. In cardiac xenografts, fibrin deposition was associated with increased plasminogen activator inhibitor-1 expression establishing that gene expression profiles in renal and cardiac xenografts differ in a quantitative manner. These findings suggest that therapeutic targets may differ for renal and cardiac xenotransplants.
Collapse
Affiliation(s)
- C. Knosalla
- Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA
| | - K. Yazawa
- Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA
| | - A. Behdad
- Transplantation and Liver Centers, Beth Israel-Deaconess Medical Center/Harvard Medical School, Boston, MA
| | - N. Bodyak
- Division of Endocrinology, Department of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
| | - H. Shang
- Transplantation and Liver Centers, Beth Israel-Deaconess Medical Center/Harvard Medical School, Boston, MA
| | - L. Bühler
- Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA
| | - S. Houser
- Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA
| | - B. Gollackner
- Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA
| | - A. Griesemer
- Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA
| | - I. Schmitt-Knosalla
- Laboratory of Immunogenetics and Transplantation, Brigham and Women's Hospital/Harvard Medical School, Boston, MA
| | | | - M. Awwad
- Previously at Immerge BioTherapeutics, Cambridge, MA
| | - D. H. Sachs
- Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA
| | - D. K. C. Cooper
- Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA
| | - K. Yamada
- Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA
| | - A. Usheva
- Division of Endocrinology, Department of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
| | - S. C. Robson
- Transplantation and Liver Centers, Beth Israel-Deaconess Medical Center/Harvard Medical School, Boston, MA
| |
Collapse
|
2
|
Gollackner B, Goh SK, Qawi I, Buhler L, Knosalla C, Daniel S, Kaczmarek E, Awwad M, Cooper DKC, Robson SC. Acute vascular rejection of xenografts: roles of natural and elicited xenoreactive antibodies in activation of vascular endothelial cells and induction of procoagulant activity. Transplantation 2004; 77:1735-41. [PMID: 15201675 DOI: 10.1097/01.tp.0000131167.21930.b8] [Citation(s) in RCA: 77] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Hyperacute rejection of vascularized discordant xenografts can now be effectively managed. However, acute vascular rejection (AVR) then ensues, resulting in graft destruction, coagulopathy, or both within weeks. The aim of this study was to determine associations between humoral responses to the xenograft and the induction of AVR, coagulopathy, or both. METHODS In vitro, heat-inactivated, naive or sensitized baboon sera containing xenoreactive natural or elicited antibodies were used to activate porcine aortic endothelial cells (PAEC) in vitro. Tissue factor expression on PAEC was determined as an index of heightened procoagulant activity. In vivo, porcine renal xenografts were transplanted into immunosuppressed baboons, and at the time of rejection or the development of a consumptive coagulopathy, biopsy specimens were obtained for studies of xenoreactive antibody binding and tissue factor expression. RESULTS In vitro, incubation of PAEC with naive baboon sera containing natural anti-Galalpha1,3Gal (Gal) antibodies resulted in minimal tissue factor induction; the addition of complement boosted procoagulant responses. Elicited xenoreactive antibodies, and to non-Gal epitopes alone, induced high amounts of procoagulant activity on PAEC; the addition of complement resulted in overt cytotoxicity. In vivo, AVR was associated with xenoreactive antibody deposition in the graft. When vascular endothelial binding of xenoreactive antibody was combined with the expression of tissue factor, consumptive coagulopathy developed irrespective of histopathologic features of AVR. CONCLUSIONS Our in vitro results indicate that elicited antibodies, potentially to non-Gal epitopes, induce endothelial cell activation and tissue factor expression; in vivo, a consumptive coagulopathy occurred when there was xenoreactive antibody deposition and increase of tissue factor.
Collapse
Affiliation(s)
- Bernd Gollackner
- Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02215, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|